PSMD14 Antibody

What is PSMD14 and what functions make it an important research target?

PSMD14 (Proteasome 26S Subunit, Non-ATPase 14), also known as POH1 or RPN11, is a metalloprotease component of the 26S proteasome that specifically cleaves 'Lys-63'-linked polyubiquitin chains. It plays a critical role in the ATP-dependent degradation of ubiquitinated proteins, maintaining protein homeostasis by removing misfolded or damaged proteins. PSMD14 participates in numerous cellular processes including cell cycle progression, apoptosis, and DNA damage repair . It contains an Mpr1-Pad1-N-terminal (MPN) domain with a JAMM motif that is essential for its deubiquitinating activity . Recent research has identified PSMD14 as a key factor promoting tumor growth in several cancers, including osteosarcoma and bladder cancer, making it a significant target for oncology research .

What applications are appropriate for PSMD14 antibodies and at what dilutions?

PSMD14 antibodies can be employed in multiple research applications with varying recommended dilutions:

It is critical to note that these dilutions serve as starting points, and researchers should perform optimization studies for each specific antibody and experimental system . Antigen retrieval methods can significantly impact results, with TE buffer pH 9.0 or citrate buffer pH 6.0 recommended for IHC applications .

What species reactivity is available for PSMD14 antibodies?

PSMD14 antibodies demonstrate varying reactivity profiles across species:

When selecting antibodies for cross-species applications, consideration should be given to the degree of sequence conservation in the epitope region. Some manufacturers provide antibodies with 100% sequence homology to multiple species but warn that reactivity must still be experimentally verified .

How can researchers validate the specificity of PSMD14 antibodies?

A comprehensive validation strategy for PSMD14 antibodies should include:

• Positive and negative controls: Use cell lines with known high expression (T24, UM-UC3, J82) and low expression (5637 cells) of PSMD14 .

• Genetic validation: Employ PSMD14 knockdown or knockout strategies to confirm signal reduction. Studies have successfully used siRNA approaches to downregulate PSMD14 in cell lines like HOS and SJSA-1 osteosarcoma cells and T24 bladder cancer cells .

• Molecular weight verification: Confirm detection at the expected 35 kDa molecular weight band, which is the calculated and observed size for PSMD14 .

• Multiple antibody comparison: Use antibodies targeting different epitopes of PSMD14 to confirm consistent results across detection methods.

• Peptide competition assays: Pre-incubate antibody with immunizing peptide to block specific binding and demonstrate signal specificity.

• Immunogen sequence analysis: Review the antibody's immunogen sequence relative to your species of interest. For example, some PSMD14 antibodies use a fusion protein (Ag2694) as immunogen, while others target specific amino acid ranges .

What are the critical parameters for optimizing Western blot protocols with PSMD14 antibodies?

For optimal Western blot detection of PSMD14:

• Sample preparation: Use RIPA buffer supplemented with protease inhibitor cocktail and phosphatase inhibitors. Research protocols indicate successful detection when lysing cells for 30 minutes in this buffer composition .

• Protein quantification and loading: Determine protein concentration using a BCA protein assay kit, and load approximately 30 μg of total protein per lane .

• Gel percentage and transfer conditions: Use 12.5% SDS-PAGE for effective separation, and transfer to PVDF membrane at 110V for 90 minutes .

• Blocking conditions: Block membranes with 5% fat-free milk for 2 hours at room temperature before antibody incubation .

• Primary antibody incubation: Dilute antibody 1:500-1:1000 in appropriate buffer and incubate overnight at 4°C for optimal signal-to-noise ratio .

• Detection method: Choose chemiluminescence or fluorescence-based detection systems based on required sensitivity and equipment availability.

• Loading controls: Include appropriate loading controls such as actin to normalize expression levels across samples .

How is PSMD14 expression correlated with clinical outcomes in cancer patients?

Multiple studies have demonstrated significant correlations between PSMD14 expression and clinical parameters:

These findings suggest PSMD14 functions as an independent prognostic factor in multiple cancer types. Immunohistochemical evaluation of PSMD14 expression could potentially serve as a biomarker for stratifying patients and predicting outcomes .

What functional roles has PSMD14 been demonstrated to play in cancer biology?

PSMD14 contributes to multiple aspects of cancer biology through its deubiquitinating activity:

• Cell proliferation: Knockdown of PSMD14 significantly suppresses cancer cell proliferation in multiple cancer types. In bladder cancer, PSMD14 depletion inhibited cell growth as measured by CCK8 assay and colony formation, while overexpression promoted growth .

• Invasion and metastasis: High PSMD14 expression correlates with increased metastatic potential in osteosarcoma patients . Functional studies demonstrate that PSMD14 influences cellular invasiveness, suggesting a role in cancer progression.

• Chemotherapy resistance: PSMD14 has been implicated in mediating therapy responses in cancer. In multiple myeloma, pharmacological inhibition of PSMD14 with O-phenanthroline (OPA) can overcome resistance to the proteasome inhibitor bortezomib .

• Molecular pathways: In bladder cancer, PSMD14 functions through the downregulation of GPX4 . In colorectal cancer, PSMD14 mediates the deubiquitination of ALK2, enhancing its stability and activating the BMP6 signaling pathway .

• Cancer stem cells: The ALK2-PSMD14 axis plays an important role in cancer stem cell maintenance in colorectal cancer, suggesting potential implications for tumor recurrence and therapeutic resistance .

What methodological approaches can be used to study PSMD14 function in cancer models?

To investigate PSMD14's role in cancer biology:

• Expression profiling: Screen cancer cell lines for endogenous PSMD14 expression using validated antibodies. Studies have identified differential expression across cell lines (high in T24, UM-UC3, J82; low in 5637 cells) .

• Genetic manipulation strategies:

  • RNA interference using PSMD14-specific siRNA or shRNA vectors

  • CRISPR-Cas9 genome editing for knockout studies

  • Overexpression models using expression vectors

• Functional assays following genetic manipulation:

  • Cell viability and proliferation (CCK8 assay, colony formation)

  • Cell migration and invasion (transwell assays)

  • Apoptosis assessment (flow cytometry)

  • In vivo tumor growth and metastasis in mouse models

• Mechanistic investigations:

  • Co-immunoprecipitation to identify PSMD14 interaction partners

  • Analysis of ubiquitination status of potential target proteins

  • Assessment of downstream signaling pathway components

• Pharmacological approaches: Study effects of PSMD14 inhibitors such as O-phenanthroline (OPA), which has been shown to inhibit proliferation, colony formation, motility, and invasion of hepatocellular carcinoma cells .

How should researchers select between different antibody formats for specific PSMD14 detection applications?

When selecting between monoclonal and polyclonal PSMD14 antibodies:

For immunohistochemical analysis of patient samples, rabbit polyclonal antibodies have been successfully employed in prognostic studies of osteosarcoma and bladder cancer tissues .

What epitope considerations are important when selecting PSMD14 antibodies for specific applications?

PSMD14 antibodies target different regions of the protein, which impacts their performance in various applications:

• N-terminal region (AA 1-95): Antibodies targeting this region have shown utility in Western blot and immunofluorescence applications .

• Central region (AA 160-300): Several commercially available antibodies target this region, which has demonstrated good immunogenicity and functional significance. These antibodies typically work well across multiple applications .

• C-terminal region: Antibodies targeting the C-terminal region can be useful for specific applications where N-terminal modifications or interactions might mask epitope accessibility.

• Regulatory Subunit 14 specific epitopes (AA 264-283): Some antibodies specifically target the regulatory subunit portion of PSMD14, which may be advantageous for studies focused on proteasome assembly and regulation .

When selecting antibodies for co-localization or protein interaction studies, researchers should consider whether the targeted epitope might be involved in protein-protein interactions that could potentially mask antibody binding.

How can researchers troubleshoot non-specific binding or high background issues with PSMD14 antibodies?

When encountering technical issues with PSMD14 antibody applications:

• Non-specific bands in Western blots:

  • Confirm expected molecular weight (35 kDa for PSMD14)

  • Increase stringency of washing steps

  • Optimize antibody concentration (test dilutions between 1:500-1:2000)

  • Include controls with PSMD14 knockdown to identify specific bands

  • Consider using more specific monoclonal antibodies if polyclonal shows cross-reactivity

• High background in immunohistochemistry:

  • Optimize antigen retrieval methods (try both TE buffer pH 9.0 and citrate buffer pH 6.0)

  • Titrate antibody concentration (test range from 1:20-1:500)

  • Extend blocking time and increase blocking reagent concentration

  • Use appropriate negative controls (omit primary antibody)

  • Consider signal amplification systems for low-expression tissues

• Poor signal-to-noise ratio in immunofluorescence:

  • Test fixation methods (paraformaldehyde vs. methanol)

  • Optimize permeabilization conditions

  • Increase the duration and stringency of washing steps

  • Use appropriate filters to minimize autofluorescence

  • Consider confocal microscopy for improved resolution and signal specificity

• Inconsistent immunoprecipitation results:

  • Vary lysis buffer compositions to preserve protein interactions

  • Pre-clear lysates thoroughly to reduce non-specific binding

  • Optimize antibody-to-bead ratio

  • Consider crosslinking antibodies to beads to prevent antibody contamination in eluates

How is PSMD14 being explored as a therapeutic target in cancer research?

Recent studies point to PSMD14 as a promising therapeutic target:

• Pharmacological inhibition: O-phenanthroline (OPA), a PSMD14 inhibitor, has demonstrated efficacy in multiple cancer models. In multiple myeloma, OPA blocks cellular proteasome function, induces apoptosis, and overcomes resistance to bortezomib . In hepatocellular carcinoma, OPA inhibits proliferation, colony formation, and invasion both in vitro and in vivo .

• Combination therapies: Research suggests that targeting PSMD14 might sensitize cancer cells to conventional therapies. Studies combining PSMD14 inhibition with standard chemotherapeutics could reveal synergistic approaches for cancer treatment.

• Cancer subtype specificity: Different cancer types show varying dependence on PSMD14, suggesting potential for targeted therapies in specific subtypes. Methodical screening of cancer cell line panels with PSMD14 inhibitors could identify particularly sensitive cancer types.

• Pathway-based approaches: Targeting PSMD14-regulated pathways, such as the reported regulation of GPX4 in bladder cancer, represents an alternative strategy to direct PSMD14 inhibition .

• Deubiquitinase specificity: Development of inhibitors with increased specificity for PSMD14 over other deubiquitinases could reduce off-target effects and improve therapeutic windows.

What are the most effective methodological approaches for studying PSMD14 in primary patient samples?

For investigating PSMD14 in clinical specimens:

• Tissue microarray analysis: Design comprehensive tissue arrays with adequate sample sizes and follow-up data. Studies have successfully employed this approach to correlate PSMD14 expression with outcomes in 181 pairs of bladder cancer and normal tissues .

• Immunohistochemical scoring systems: Develop consistent scoring methods based on staining intensity and percentage of positive cells. This approach has revealed significant associations between PSMD14 expression and clinicopathological features .

• Multi-marker panels: Combine PSMD14 staining with other relevant biomarkers to develop more robust prognostic signatures.

• Patient-derived xenografts (PDX): Establish PDX models from tumors with varying PSMD14 expression to test targeted therapies in more clinically relevant systems.

• Ex vivo culture systems: Culture primary patient samples with PSMD14 inhibitors to assess therapeutic sensitivity in personalized medicine applications.

How can PSMD14 antibodies be used to investigate the protein's role in non-cancer diseases and normal physiological processes?

Beyond cancer research, PSMD14 antibodies can illuminate the protein's roles in:

• Neurodegenerative disorders: Given PSMD14's role in protein homeostasis, investigate its expression and function in disorders like Alzheimer's and Parkinson's disease using immunohistochemistry in brain tissues.

• Developmental biology: Study PSMD14 expression patterns during embryonic development using whole-mount immunostaining protocols.

• Stem cell biology: Investigate PSMD14's reported roles in pluripotency and differentiation through immunofluorescence co-localization with stem cell markers.

• Aging research: Examine age-related changes in PSMD14 expression and activity in various tissues using validated antibodies.

• Immune system regulation: Explore PSMD14's involvement in immune inflammatory responses through flow cytometry and immunohistochemistry of immune tissues.

• DNA damage repair mechanisms: Investigate PSMD14's established role in DNA damage repair through co-immunoprecipitation studies to identify interaction partners in different damage response pathways.